AR-v7 protein expression is regulated by protein kinase and phosphatase

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33743-33754

  Li, Yinan ^a   Xie, Ning ^a   Gleave, Martin E ^a   Rennie, Paul S ^a   Dong, Xuesen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AR v7; Castration resistant prostate cancer; PP 1 and Akt; Protein stability; Serine phosphorylation

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR 7; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE B; PROTEIN MDM2; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; ENZALUTAMIDE; MDM2 PROTEIN, HUMAN; PHENYLTHIOHYDANTOIN; PHOSPHATASE; PROTEASOME; PROTEIN KINASE; SERINE;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RNA SPLICING; UBIQUITINATION; UPREGULATION; ALTERNATIVE RNA SPLICING; ANALOGS AND DERIVATIVES; CHEMISTRY; CYTOPLASM; DISEASE COURSE; GENE EXPRESSION REGULATION; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; CYTOPLASM; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; PROTEIN PHOSPHATASE 1; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ANDROGEN; SERINE; UBIQUITINATION;

EID: 84946087758     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5608     Document Type: Article

References (31)

1. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J and Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature genetics. 1995; 9:401-406.
2. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN and Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. The New England journal of medicine. 1995; 332:1393-1398.
3. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer research. 2008; 68:6407-6415.
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012; 367:1187-1197.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, et al. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine. 2011; 364:1995-2005.
6. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA and Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer research. 2013; 73:483-489.
7. Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y and Shi G. Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer. Scientific reports. 2015; 5:7654.
8. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England journal of medicine. 2014; 371:1028-1038.
9. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS and Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormonerefractory prostate cancer. Cancer research. 2009; 69:16-22.
10. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J and Qiu Y. A novel androgen receptor splice variant is upregulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer research. 2009; 69:2305-2313.
11. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR and Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer research. 2012; 72:3457-3462.
12. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E and Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2014; 33:3140-3150.
13. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH and Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer research. 2011; 71:2108-2117.
14. van der Steen T, Tindall DJ and Huang H. Posttranslational modification of the androgen receptor in prostate cancer. International journal of molecular sciences. 2013; 14:14833-14859.
15. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH and Hung MC. HER-2/neu promotes androgenindependent survival and growth of prostate cancer cells through the Akt pathway. Cancer research. 2000; 60:6841-6845.
16. Lin HK, Yeh S, Kang HY and Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:7200-7205.
17. Chen S, Kesler CT, Paschal BM and Balk SP. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. The Journal of biological chemistry. 2009; 284:25576-25584.
18. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N and Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell. 2011; 19:575-586.
19. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG and Wu H. Cell autonomous role of PTEN in regulating castrationresistant prostate cancer growth. Cancer cell. 2011; 19:792-804.
20. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Nelson PS, Liu XS, Brown M and Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer cell. 2011; 20:457-471.
21. Lin HK, Wang L, Hu YC, Altuwaijri S and Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. The EMBO journal. 2002; 21:4037-4048.
22. Li L, Ren CH, Tahir SA, Ren C and Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Molecular and cellular biology. 2003; 23:9389-9404.
23. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A and Wikstrom P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PloS one. 2011; 6:e19059.
24. Kong D, Sethi S, Li Y, Chen W, Sakr WA, Heath E and Sarkar FH. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. The Prostate. 2015; 75:161-174.
25. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, Gambhir SS, Lee P, Sartor O, Flemington EK, Zhang H, Hu CD and Dong Y. Androgen receptor splice variants dimerize to transactivate target genes. Cancer research. 2015; 75:3663-71.
26. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, et al. The mutational landscape of lethal castrationresistant prostate cancer. Nature. 2012; 487:239-243.
27. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer cell. 2010; 18:11-22.
28. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C and Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:1590-1600.
29. Li H, Xie N, Gleave ME and Dong X. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. Oncotarget. 2015; 6:20474-84.
30. Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M and Dong X. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. The Journal of clinical endocrinology and metabolism. 2013; 98:2887-2896.
31. Liu L, Li Y, Xie N, Shynlova O, Challis JR, Slater D, Lye S and Dong X. Proliferative action of the androgen receptor in human uterine myometrial cells-a key regulator for myometrium phenotype programming. The Journal of clinical endocrinology and metabolism. 2013; 98:218-227.